Rhythm’s Imcivree Fails Late-Stage Weight Loss Trial in Rare Obesities

The Phase 3 EMANATE study is a basket trial looking at the efficacy of Rhythm Pharmaceuticals’ injectable obesity drug across four types of obesities driven by specific genetic mutations.